Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
|Articles|February 17, 2005
INTERPHEX2005
Interphex
Advertisement
INTERPHEX2005 is your best source for the latest ideas, products and solutions for the entire scope of the pharmaceutical industry. The event features over 950 exhibiting companies and offers education and technology for every phase of the drug development and manufacturing cycle including facilities, IT, sourcing and services. Tap into educational programs that focus on the unique needs of the industry.
Attend April 2628, 2005 at Jacob K. Javits Convention Center, NYyour best resource for what's new, what's happening, and what's changing in your business. For complete event information and on-line registration, visit
Advertisement
Related to this article
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
4
AAPS PharmSci 360 2026: Spray Drying and ASD
5